Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options
Tamoxifen is commonly prescribed in hormone receptor-positive breast cancer but also associated with weight gain, which can complicate survivorship care. This narrative review summarizes evidence on tamoxifen-associated weight gain and outlines pharmacologic weight management options in this population.
To explore the prevalence, mechanisms, and management options for weight gain associated with tamoxifen therapy in breast cancer survivors, emphasizing the importance of addressing this issue for improved health outcomes.
Key Findings:
Tamoxifen therapy is associated with significant weight gain in a substantial proportion of women, necessitating proactive management.
Weight gain mechanisms include appetite disruption, altered metabolism, and reduced energy expenditure, which have direct implications for patient care.
Excess weight in breast cancer survivors correlates with increased health risks, underscoring the importance of weight management.
Lifestyle modifications are recommended as first-line interventions, with pharmacotherapy for higher BMI patients to enhance treatment outcomes.
Interpretation:
Weight management is crucial for breast cancer survivors on tamoxifen, necessitating a comprehensive approach that includes lifestyle changes and potential pharmacotherapy, tailored to individual patient needs.
Limitations:
Variability in individual responses to tamoxifen and weight management strategies may affect treatment outcomes.
Limited long-term data on the effectiveness of pharmacotherapy in this population highlights the need for ongoing research.
Conclusion:
Addressing tamoxifen-associated weight gain through lifestyle and pharmacotherapy is essential for improving health outcomes in breast cancer survivors, emphasizing the urgency of this issue.
A Keck Medicine of USC breast surgeon discusses the FDA’s decision — and whether using HRT to treat menopause symptoms actually affects breast cancer risk.
